HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
WEDNESDAY, May 5, 2021 (HealthDay News) -- Nearly 10 million cancer screenings have been missed in the United States during the coronavirus pandemic, researchers report.
The investigators analyzed data on three types of cancer for which early screenings are most beneficial — breast, colon and prostate — and found that 9.4 million screenings for these cancers did not occur in the United States due to COVID-19.
Screenings for all three types of cancer fell sharply. For example, there was a 90% decline in breast cancer screenings in April 2020, according to the study published online April 29 in JAMA Oncology.
"As a physician, I wasn't surprised to see that screenings had declined, but this study measures by how much," said study author Dr. Ronald Chen, associate director of health equity at the University of Kansas Cancer Center. "This study makes it clear that this is a large public health issue."
Routine screening helps detect cancer at an early stage when it is most curable. Millions of people missing cancer screenings because of the COVID-19 pandemic will mean the delay in the detection of cancer for some, meaning it will be more advanced when it's diagnosed.
"Unfortunately, by causing cancellations of appointments and cancer screenings, COVID will indirectly cause an increase in cancer deaths — another negative consequence of COVID that has not yet received much public attention," Chen said in a university news release.
It's crucial for the public and health care providers to understand the urgency of getting cancer screenings back on track, he emphasized.
"There needs to be a concerted public health educational campaign across the country to reinforce the importance of cancer screening," Chen said. "Hospitals across the country also need to devote effort to contact patients to reschedule canceled screening tests, in order to minimize the delay in screening and cancer diagnoses from the missed tests."
The study also found that telehealth visits, which were widely used for the first time during the pandemic, were associated with better screening rates.
"Telehealth has a measurable positive effect on whether patients get their cancer screenings," Chen said. "This study also justifies a continued use of telehealth even after the pandemic."
There's more on cancer screening at the U.S. National Cancer Institute.
SOURCE: University of Kansas Cancer Center, news release, April 30, 2021
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on May 24, 2022